We're excited to announce the combination of Berkeley Lights and IsoPlexis, bringing together the Beacon and IsoSpark platforms to form the premier functional cell biology company. Visit Site

The first IND application incorporating monoclonality assurance data from the Beacon® system has been approved by the FDA

The Beacon system’s optofluidic chip technology and integrated imaging provide direct evidence of >99% monoclonality, without the manual effort and uncertainty of traditional methods. Optofluidic chip NanoPen™ chambers are 700x smaller than a microplate well leaving nowhere for “ghost cells” to hide.

Automated imaging at every step for a complete visual record of every clone


Clonality assurance independently validated

“Clonality assurance on the Berkeley Lights Beacon platform follows the same imaging and validation paradigm [as microscopic imaging and verification]. However, through improved integrated imaging capability, cell detection algorithms, and in‐process quality controls, the Beacon provides an overall stronger data package for single cell progenitor assurance.”

Kim, L et al., Amgen. Read paper.

Overall clonality assurance rates determined by Le et al.

Want to learn more?

Download the application note on: FDA-Accepted Monoclonality Assurance on The Beacon® Optofluidic System for Cell Line Development to learn how Beacon system’s superior cloning technology, automated imaging capabilities, and in-process quality controls provide definitive evidence of monoclonality to support regulatory approvals.